Investors sold shares of Amgen, Inc. (NASDAQ:AMGN) on strength during trading on Monday. $142.36 million flowed into the stock on the tick-up and $264.33 million flowed out of the stock on the tick-down, for a money net flow of $121.97 million out of the stock. Of all stocks tracked, Amgen had the 0th highest net out-flow for the day. Amgen traded up $1.41 for the day and closed at $174.87

A number of brokerages have commented on AMGN. Piper Jaffray Companies decreased their price target on shares of Amgen from $194.00 to $190.00 and set an “overweight” rating for the company in a research note on Friday, February 2nd. Atlantic Securities lowered shares of Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 price target for the company. in a research note on Monday, February 5th. Morgan Stanley decreased their price target on shares of Amgen from $204.00 to $196.00 and set an “overweight” rating for the company in a research note on Friday, February 2nd. BMO Capital Markets boosted their price target on shares of Amgen from $192.00 to $202.00 and gave the company a “market perform” rating in a research note on Friday, February 2nd. Finally, Mizuho restated a “buy” rating and set a $200.00 price target (up previously from $192.00) on shares of Amgen in a research note on Monday. Sixteen research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $191.84.

The company has a debt-to-equity ratio of 1.35, a current ratio of 5.49 and a quick ratio of 5.17. The firm has a market capitalization of $128,650.00, a price-to-earnings ratio of 68.69, a PEG ratio of 2.15 and a beta of 1.42.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.03 by ($0.14). The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. Amgen’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same period last year, the firm posted $2.89 earnings per share. equities research analysts expect that Amgen, Inc. will post 13.22 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be issued a $1.32 dividend. This is an increase from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 dividend on an annualized basis and a dividend yield of 3.00%. The ex-dividend date is Wednesday, February 14th. Amgen’s payout ratio is 178.29%.

Amgen declared that its Board of Directors has authorized a share buyback program on Wednesday, October 25th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.

In related news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $176.83, for a total value of $269,665.75. Following the transaction, the executive vice president now directly owns 56,106 shares of the company’s stock, valued at approximately $9,921,223.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.19% of the stock is currently owned by insiders.

Large investors have recently modified their holdings of the stock. Baker Ellis Asset Management LLC bought a new stake in Amgen in the 3rd quarter valued at about $108,000. Jackson Grant Investment Advisers Inc. raised its stake in Amgen by 0.8% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock valued at $110,000 after acquiring an additional 5 shares during the period. Phocas Financial Corp. bought a new stake in Amgen in the 2nd quarter valued at about $110,000. Barrow Hanley Mewhinney & Strauss LLC raised its stake in Amgen by 110.7% in the 4th quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 647 shares of the medical research company’s stock valued at $113,000 after acquiring an additional 340 shares during the period. Finally, Omnia Family Wealth LLC raised its stake in Amgen by 25.3% in the 2nd quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock valued at $125,000 after acquiring an additional 147 shares during the period. 78.95% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Investors Sell Shares of Amgen (AMGN) on Strength (AMGN)” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://theolympiareport.com/2018/02/14/investors-sell-shares-of-amgen-amgn-on-strength-amgn.html.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.